Niza et al. used TAB to modify Dasatinib-encapsulated nanoparticles to target HER2 overexpressing breast cancer cells.202 Fu et al. also used TAB to modify lipopolymer hybrid nanoparticles loaded with cisplatin (CIS) and 5-fluoropyrimidine (5-FU), providing a new tumor treatment strategy with higher efficacy and fewer side effects.203. This evidence concerns the gene ERBB2 and breast carcinoma.